Sort
23,748 grants matching “melanoma”
Community Outreach and Engagement
$224,973Pamela Carmen Hull · University Of Kentucky · P30 · FY2023 · CA
Directed Chemotherapy Delivery for Leptomeningeal Metastases
$224,970Aaron Richard McCabe · Minnetronix, Inc. · R41 · FY2016 · CA
DEVELOPMENTAL ORIGINS AND HOMEOSTATIC MECHANISMS UNDERLYING ADULT PHENOTYPE
$224,956David M Parichy · University Of Virginia · R35 · FY2018 · GM
Orphan Nuclear Receptor as Novel Drug Discovery Target for Cancer Immunotherapy
$224,954Haiyan Tao · Orphagen Pharmaceuticals · R43 · FY2015 · CA
Promoting Tumor Immunity by Cross-linking B7-DC
$224,952Larry R Pease · Mayo Clinic Rochester · R01 · FY2013 · CA
Circulating Vitamin D Levels and Risk of Breast and Colorectal Cancer: a Pooled A
$224,882Stephanie A Smith-Warner · Harvard School Of Public Health · R01 · FY2012 · CA
Low-dose IL2-based Immunomodulatory therapy for Stroke
$224,879Ridong Chen · Apt Therapeutics, Inc. · R43 · FY2014 · NS
Microfluidic technology to isolate tumoricidal T-cells from peripheral blood
$224,762Venktesh Shirure · University Of California At Davis · R61 · FY2025 · CA
Core B: Proteomics Core.
$224,721Peter Kent Jackson · Stanford University · P01 · FY2024 · CA
Inflammatory mediators and UV-induced carcinogenesis
$224,720Stephen E Ullrich · University Of Tx Md Anderson Can Ctr · R01 · FY2008 · CA
Inflammatory mediators and UV-induced carcinogenesis
$224,720Stephen E Ullrich · University Of Tx Md Anderson Can Ctr · R01 · FY2007 · CA
Inflammatory mediators and UV-induced carcinogenesis
$224,720Stephen E Ullrich · University Of Tx Md Anderson Can Ctr · R01 · FY2009 · CA
Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy
$224,700Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2020 · CA
Novel Anti-inflammmatory Antibody Therapy for Inflammatory Bowel Disease
$224,665Susan C Wright · Panorama Research, Inc. · R43 · FY2016 · DK
PEPTIDE VACCINES WITH/WITHOUT GMCSF IN STAGE IV MELANOMA
$224,618University Of Pittsburgh At Pittsburgh · R01 · FY2003 · CA
Receptor Crosstalk in HNSCC Metastatic Progression
$224,569Steven A. Rosenzweig · Medical University Of South Carolina · R01 · FY2012 · CA
Receptor Crosstalk in HNSCC Metastatic Progression
$224,569Steven A. Rosenzweig · Medical University Of South Carolina · R01 · FY2009 · CA
Receptor Crosstalk in HNSCC Metastatic Progression
$224,569Steven A. Rosenzweig · Medical University Of South Carolina · R01 · FY2010 · CA
Receptor Crosstalk in HNSCC Metastatic Progression
$224,569Steven A. Rosenzweig · Medical University Of South Carolina · R01 · FY2016 · CA
Receptor Crosstalk in HNSCC Metastatic Progression
$224,569Steven A. Rosenzweig · Medical University Of South Carolina · R01 · FY2015 · CA
Programming Metabolically Fit TILs for Immunotherapy
$224,559Shikhar Mehrotra · Lipo-Immuno Tech, Llc · R41 · FY2020 · CA
Core 2-MelCore biospecimens
$224,556Jeffrey E Gershenwald · University Of Tx Md Anderson Can Ctr · P50 · FY2021 · CA
KIR2DL2 Immune Checkpoint as Modulator of T-Cell Effector Function
$224,506Daniel Abate-Daga · H. Lee Moffitt Cancer Ctr & Res Inst · R21 · FY2024 · CA
Modulation of Bone Morphogenic Protein signaling for cancer immunotherapy
$224,500Piotr J Kraj · Augusta University · R21 · FY2012 · AI
Using Single Cell Analysis to identify therapeutic vulnerabilities in leptomeningeal melanoma metastases
$224,460Keiran Smalley · H. Lee Moffitt Cancer Ctr & Res Inst · R21 · FY2018 · CA